IGF-1 LR3 1mg (Long R3 Insulin-Like Growth Factor-1)

Product Specifications:
• Structural Formula: 83-amino acid recombinant single-chain polypeptide
• Structural Feature: Substitution of Glu for Arg at position 3, plus a 13-amino acid N-terminal extension
• Total Active Mass: 1mg per vial
• Molecular Weight: 9111.6 g/mol
• Physical Profile: Homogeneous, white lyophilized cake
• Purity Level: ≥98.0% individual component purity verified via HPLC analysis

Product Overview:
IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a highly engineered, synthetic analog of endogenous human IGF-1. Standard native human IGF-1 possesses a short half-life in vitro due to rapid inactivation by insulin-like growth factor-binding proteins (IGFBPs). By substituting glutamic acid for arginine at the 3rd position (R3) and integrating a 13-amino acid extension peptide at the N-terminus, IGF-1 LR3 is structurally altered to display a drastically reduced binding affinity for these inhibitory proteins, vastly extending its biological stability and operational window in research media.

Investigational Vectors:
1. Hyperplasia and Myogenesis: Researchers study the compound’s binding kinetics at the type 1 IGF receptor (IGF-1R) locus to observe downstream tyrosine kinase activation, cellular proliferation, and myoblast differentiation pathways.
2. Intracellular Transport Mechanics: In vitro and animal models evaluate the compound’s capacity to stimulate direct amino acid transport and accelerate glycogen synthesis inside targeted cell lines.
3. Protein Synthesis Transduction: Investigated for its regulatory behavior in skeletal muscle cellular structures, specifically evaluating how it upregulates the AKT/mTOR signaling pathways to suppress baseline protein degradation.

Open COA